The US biotech PellePharm has announced positive top-line results from a UK-based Phase II trial of its novel topical hedgehog signaling pathway inhibitor, patidegib, in Gorlin syndrome and basal cell carcinoma. The company says it is aiming to start a Phase III study of the compound in the first half of 2018, following discussions with the US FDA, and supported by a planned Series C round of funding.
Topical patidegib is designed to tackle one of the major drawbacks of hedgehog signaling inhibitors, namely that they are associated...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)